Literature DB >> 19030176

Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals.

Frank Schüler1, Lars Dölken, Carsten Hirt, Thomas Kiefer, Tobias Berg, Gerhard Fusch, K Weitmann, W Hoffmann, Christoph Fusch, Siegfried Janz, Charles S Rabkin, Gottfried Dölken.   

Abstract

The t(14;18) translocation is a common genetic aberration that can be seen as an early step in pathogenesis of follicular lymphoma (FL). The significance of low level circulating t(14;18)-positive cells in healthy individuals as clonal lymphoma precursors or indicators of risk is still unclear. We determined the age dependent prevalence and frequency of BCL2/IgH rearrangements in 715 healthy individuals ranging from newborns to octo- and nonagenarians. These results were compared with number of circulating t(14;18)-positive cells in 108 FL patients at initial presentation. The overall prevalence of BCL2/IgH junctions in this large sample was 46% (327/715). However, there was a striking dependence upon age. Specifically, among individuals up to 10 years old, none had detectable circulating t(14;18)-positive cells. In the age groups representing 10-50 years old, we found a steady elevation in the prevalence of BCL2/IgH junctions up to a prevalence of 66%. Further increases of the prevalence in individuals older than 50 years were not seen. The mean frequency of BCL2/IgH junctions in healthy individuals > or =40 years (18-26 x 10(-6)) was significantly higher than in younger subjects (7-9 x 10(-6)). Four percent (31/715) of individuals carried more than one t(14;18)-positive cell per 25,000 peripheral blood mononuclear cells (PBMNCs). In comparison, 108 stage III/IV FL patients had a median number of circulating t(14;18)-positive malignant FL cells of about 9200/1 million PBMNCs (range 7-1,000,000). These findings will further improve the understanding of the relevance of t(14;18)-positive cells in healthy individuals as a risk marker toward the development into lymphoma precursors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19030176      PMCID: PMC4216731          DOI: 10.1002/ijc.23958

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study.

Authors:  P W Johnson; K Swinbank; S MacLennan; D Colomer; B Debuire; T Diss; J Gabert; R K Gupta; A Haynes; M Kneba; M S Lee; E Macintyre; E Mensink; M Moos; G J Morgan; A Neri; A Johnson; G Reato; G Salles; M B van't Veer; J L Zehnder; E Zucca; P J Selby; F E Cotter
Journal:  Ann Oncol       Date:  1999-11       Impact factor: 32.976

Review 2.  Chromosomal translocation t(14;18) in healthy individuals.

Authors:  Frank Schüler; Carsten Hirt; Gottfried Dölken
Journal:  Semin Cancer Biol       Date:  2003-06       Impact factor: 15.707

Review 3.  Detection of minimal residual disease.

Authors:  G Dölken
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

Review 4.  Detection and monitoring of minimal residual disease by quantitative real-time PCR.

Authors:  Frank Schüler; Gottfried Dölken
Journal:  Clin Chim Acta       Date:  2005-09-08       Impact factor: 3.786

5.  Variability of quantitative polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicenter study.

Authors:  Angela J Darby; Stuart Lanham; Pierre Soubeyran; Peter W M Johnson
Journal:  Haematologica       Date:  2005-12       Impact factor: 9.941

6.  Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals.

Authors:  Carsten Hirt; Gottfried Dölken; Siegfried Janz; Charles S Rabkin
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998

7.  Chromosome abnormalities in poorly differentiated lymphocytic lymphoma.

Authors:  S Fukuhara; J D Rowley; D Variakojis; H M Golomb
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

8.  Detection of t(14;18) carrying cells in bone marrow and peripheral blood from patients affected by non-lymphoid diseases.

Authors:  O Rauzy; S Galoin; J J Chale; D Adoue; J L Albarede; G Delsol; T al Saati
Journal:  Mol Pathol       Date:  1998-12

9.  In situ localization of follicular lymphoma: description and analysis by laser capture microdissection.

Authors:  Peijie Cong; Mark Raffeld; Julie Teruya-Feldstein; Lynn Sorbara; Stefania Pittaluga; Elaine S Jaffe
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

10.  VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.

Authors:  Alexander Egle; Alan W Harris; Mary L Bath; Lorraine O'Reilly; Suzanne Cory
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

View more
  33 in total

1.  hnRNP L-dependent protection of normal mRNAs from NMD subverts quality control in B cell lymphoma.

Authors:  Aparna Kishor; Zhiyun Ge; J Robert Hogg
Journal:  EMBO J       Date:  2018-12-07       Impact factor: 11.598

2.  Methylation of the nonhomologous end joining repair pathway genes does not explain the increase of translocations with aging.

Authors:  Idoia Martín-Guerrero; Elena de Prado; Elixabet Lopez-Lopez; Maite Ardanaz; Juan Carlos Vitoria; Luis A Parada; Cristina García-Orad; Africa García-Orad
Journal:  Age (Dordr)       Date:  2014-11-16

Review 3.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

Review 4.  Current challenges in the management of follicular lymphoma.

Authors:  Maryam Sarraf Yazdy; Chaitra Ujjani
Journal:  Int J Hematol Oncol       Date:  2017-06-30

Review 5.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

Review 6.  From genetics to the clinic: a translational perspective on follicular lymphoma.

Authors:  Sarah Huet; Pierre Sujobert; Gilles Salles
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

7.  FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Authors:  Anja Mottok; Vindi Jurinovic; Pedro Farinha; Andreas Rosenwald; Ellen Leich; German Ott; Heike Horn; Wolfram Klapper; Michael Boesl; Wolfgang Hiddemann; Christian Steidl; Joseph M Connors; Laurie H Sehn; Randy D Gascoyne; Eva Hoster; Oliver Weigert; Robert Kridel
Journal:  Blood       Date:  2017-11-09       Impact factor: 22.113

Review 8.  Novel Therapy Approaches to Follicular Lymphoma.

Authors:  Michael Northend; William Townsend
Journal:  Drugs       Date:  2021-03       Impact factor: 9.546

9.  Circulating t(14;18)-positive cells in healthy individuals: association with age and sex but not with smoking.

Authors:  Carsten Hirt; Kerstin Weitmann; Frank Schüler; Thomas Kiefer; Charles S Rabkin; Wolfgang Hoffmann; Gottfried Dölken
Journal:  Leuk Lymphoma       Date:  2013-05-07

Review 10.  Progress against follicular lymphoma.

Authors:  Jonathan H Schatz; Elisa Oricchio; Soham D Puvvada; H Guido Wendel
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.